Table 2 Clinical characteristics of 506... | American Society of Hematology

Table 2

Clinical characteristics of 506 de novo DLBCL with GCB or ABC subtypes treated with R-CHOP: comparison between patients with or without TP53 mutations

	Overall (N = 506)			GCB (n = 258)			ABC (n = 241)
	WT-TP53	MUT-TP53	P	WT-TP53	MUT-TP53	P	WT-TP53	MUT-TP53	P
Patients, n	395	111		190	68		198	43
Age
< 60 y	163	43		94	33		64	10
≥ 60 y	232	68	.2073	96	35	.8937	134	33	.2427
Sex
F	164	46		82	27		77	19
M	231	65	.9883	108	41	.6209	121	24	.5201
Stage
I-II	183	54		104	33		74	21
III-IV	192	57	.9776	72	35	.1361	118	22	.2137
B symptoms
No	232	66		119	41		108	25
Yes	112	29	.7073	44	20	.3929	67	9	.1900
LDH
Normal	129	27		71	14		57	13
Elevated	223	76	.0497	95	48	.0050	123	28	.9906
No. of extranodal sites
0-1	299	87		143	53		145	32
≥ 2	75	21	.889	32	13	.8020	47	10	.9270
Performance status
0-1	289	89		133	55		149	34
≥ 2	46	11	.4775	17	6	.7517	29	5	.5891
Size of largest tumor
< 7.5 cm	241	60		114	38		124	22
≥ 7.5 cm	63	29	.0201	27	21	.0130	34	8	.5349
IPI risk group
0-2	225	66		118	41		100	25
3-5	122	36	.9799	43	20	.3698	79	16	.5513
Therapy response*
CR	316	67	< .0001	153	41	.0009	156	26	.0113
PR	45	23		19	14		26	9
SD	11	7		6	4		5	3
PD	23	14		12	9		11	5

	Overall (N = 506)			GCB (n = 258)			ABC (n = 241)
	WT-TP53	MUT-TP53	P	WT-TP53	MUT-TP53	P	WT-TP53	MUT-TP53	P
Patients, n	395	111		190	68		198	43
Age
< 60 y	163	43		94	33		64	10
≥ 60 y	232	68	.2073	96	35	.8937	134	33	.2427
Sex
F	164	46		82	27		77	19
M	231	65	.9883	108	41	.6209	121	24	.5201
Stage
I-II	183	54		104	33		74	21
III-IV	192	57	.9776	72	35	.1361	118	22	.2137
B symptoms
No	232	66		119	41		108	25
Yes	112	29	.7073	44	20	.3929	67	9	.1900
LDH
Normal	129	27		71	14		57	13
Elevated	223	76	.0497	95	48	.0050	123	28	.9906
No. of extranodal sites
0-1	299	87		143	53		145	32
≥ 2	75	21	.889	32	13	.8020	47	10	.9270
Performance status
0-1	289	89		133	55		149	34
≥ 2	46	11	.4775	17	6	.7517	29	5	.5891
Size of largest tumor
< 7.5 cm	241	60		114	38		124	22
≥ 7.5 cm	63	29	.0201	27	21	.0130	34	8	.5349
IPI risk group
0-2	225	66		118	41		100	25
3-5	122	36	.9799	43	20	.3698	79	16	.5513
Therapy response*
CR	316	67	< .0001	153	41	.0009	156	26	.0113
PR	45	23		19	14		26	9
SD	11	7		6	4		5	3
PD	23	14		12	9		11	5

LDH indicates lactate dehydrogenase; PR, partial response; SD, stable disease; and PD, progressive disease.

For therapy response, we calculated P values as CR versus other responses.

View Large

This Feature Is Available To Subscribers Only